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KETAMINE. Success or failure with the use of 
ketamine depends largely on three factors : 
1. Awareness that ketamine is different from 
traditional anesthetics. These differences in-
clude the following : 
Ketamine, unlike traditional anesthetics 
which cause total depression of the central 
nervous system, affects selectively pain con-
duction and perception systems, stimulating 
one area of the brain while simultaneously 
depressing another ("dissociation") . 
Ketamine stimulates the cardiovascular sys-
tem while traditional anesthetics depress car-
diovascular function. 
Ketamine has antiarrhythmic properties while 
traditional anesthetics do not. They may 
even precipitate arrhythmias. 
Ketamine maintains or even exaggerates pro-
tective reflexes while traditional anesthetics 
suppress them. 
Ketamine ensures airway patency, provided 
no mechanical airway obstruction is present, 
while traditional anesthetics require addi-
tional tools and techniques. 
Ketamine does not produce the traditional 
"anesthetized" appearance in the patient, but 
rather a characteristic "disconnected" ap-
pearance. 
2. Knowledge of the criteria used for selection 
of patients for ketamine anesthesia: 
* Presented at the 25th Annual Stoneburner Lecture 
Series, February 25, 1972, at the Medical College of Vir-
ginia, Richmond. 
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Use of ketamine predominantly in infants 
and children up to 14 years of age. 
The use of ketamine in adult patients is con-
fined to surgical conditions for which keta-
mine has proven to be particularly advan-
tageous, safe, and superior to conventional 
anesthetic agents and methods ( see under 3). 
Narcotic addicts and patients with a history 
of chronic alcohol abuse or suffering from 
acute alcohol intoxication are poor candi-
dates for ketamine anesthesia because in 
these patients even excessive doses of keta-
mine may fail to control body movements. 
3. Limiting the use of ketamine anesthesia to 
the following specific surgical areas and con-
ditions: 
Surgical treatment of burns* 
Neurodiagnostic procedures such as pneu-
moencephalography, ventriculography, mye-
lography, and carotid arteriography. 
Out-patient ophthalmology (tonometry, fun-
doscopy, gonioscopy). 
Out-patient oral surgery (tooth extraction, 
surgery on the gingiva). 
Out-patient otology ( myringotomy, insertion 
of myringeal tubes, removal of foreign body 
from ear canal) . 
Out-patient plastic surgery (removal of nevi, 
suturing of laceration, removal of scars). 
* Patients of all ages may be included. 
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Elective orthopedic surgery ( reduction of 
congenital hip luxation, spicacast applica-
tion) . 
Emergency orthopedic surgery ( closed re-
duction of fractures). 
Repeated manipulation under anes thesia ( ir-
radiation of inoperable int raocular or intra-
cranial les ions) . 
Induction of anesthesia in high-risk pa-
tients, including asthmatics, prior to the use 
of the principle anesthetic. Ketamine-in-
duced cardiovascular stimulation and its re-
laxant effect on bronchial musculature offer 
significant advantages over conventional an-
esthetic agents. * 
Cardiac catheteri zation. 
Open heart surgery, particul arly involving 
patients with minimal or no cardiac reserve. 
Cardiovascular stimulation and antiarrhyth-
mic affects of ketamine offer prime advan-
tages over traditional anesthetics.* 
Emergency surgery in patients suffering 
from hypovolemia or shock-like conditions. 
Ketamine may be used fo r induction or to 
enhance minim al conventional anesthesia. It 
offers the advantage of ensuring cardiovas-
cular support until conventional measures to 
control hypovolemia and shock can be in-
stituted and become effective.* 
Contraindications. Ketamine is contraindicated 
with hypertension, history of cerebrovascul ar acci-
dent , upper respiratory infection, increased cerebro-
spinal fluid pressure, abdominal surgery, and other 
surgery involving visceral pain ( unless supplemented 
with conventional anesthetics). 
Technique of Administration of Ketamine. 
Pre-anesthetic medication: Infants and children 
receive scopolamine 0.1 to 0.4 mg, depending on age 
and weight, given int ramuscularly 1/2 to 1 hour prior 
to surgery to counteract ketamine-induced hypersali-
vation. Pentobarbital or secobarbital (0.5 to 1 mg 
per pound) may be given fo r additional sedation. 
Adult patients receive a tranquilizer with anti-
psychotic properties, preferably droperidol ( 1 to 2 ml) 
or Innovar® ( 1 to 2 ml ) combined with 0.4 mg of 
atropine administered int ramuscularly 1/2 to 1 hour 
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prior to surgery. Other combinations of narcotic 
analges ics, tranquilizers, and ataractics have proven 
less effective as compared with the above-mentioned 
medication. 
Omitting narcotics or barbitu ra tes in the pre-
anesthetic medication will significantly shorten re-
covery time. No pre-anesthetic medication is given to 
patients undergoing ambul atory surgery provided 
that the surgical procedure is limited to 15 minutes. 
Induction: With the int ravenous route, the initial 
dose of ketamine ranges from 1 to 2 mg per kg de-
pending on the physical state of the patient. It is 
recommended that ketamine be administered slowly, 
over a period of 30 to 60 seconds. More rapid ad-
ministration may result in respi ratory depression . 
With the intramuscul ar route, the initial dose of 
ketamine ranges from 6 to 12 mg per kg. 
Main tenance: Supplemental increments of 1/ 2 
to 1/ 3 of the full induction dose may be administered 
intravenously every 8 to 10 minutes or intramuscu-
larly every 20 to 30 minutes, or when movements of 
head or extremities indicate lightening of anesthesia. 
Complications. The foll owing complications may 
be encountered : 
Temporary augmentation of pulse rate and 
blood pressure beginning shortly after injec tion of the 
drug. This cardiovascular-stimulating effect of keta-
mine may prove beneficial in certain circumstances, 
for example, in the presence of hypotension or shock-
like states . In hypertensive individuals, however, 
stimulation may be considered undesirable or unsafe. 
T ransient depression of respiration in response 
to rapid intravenous injection or in connection with 
an overdose of ketamine. 
Paroxysmal coughing in the presence of upper 
respi ratory infection, occurring immediately follow-
ing the initial injection of ketamine and recurring 
with supplemental increments. 
Vivid dreaming, with or without psychomotor 
activity, confusion, and irrational behavior occurring 
du ring emergence from anesthesia. This complication 
is more often observed in adults th an in children and 
infa nts. 
Tonic and clonic muscle movements resembling 
convulsive seizures occurring in certain patients with-
out electroenceph alographic evidence of seizure ac-
tivity. 
Erythema or morbillifo rm rash occurring subse-
quent to the initial injection of ketamine. The skin 
erupt ion is transient and usually confi ned to face, 
neck, and upper chest. 
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Treatment of Complications. Proper pre-anes-
thetic medication as outlined above may signficantly 
suppress or even eliminate most adverse reactions. 
This holds particularly true with regard to post-anes-
thetic emergence delirium reactions. The incidence 
and degree of these psychic disturbances can be fur-
ther minimized by avoiding premature verbal or 
tactile stimulation of the patient ( "sensory depriva-
tion") . 
Post-anesthetic emergence delirium reactions, 
should they occur in spite of proper pre-anesthetic 
medication, may be successfully treated with intra-
venous droperidol-1 to 2 ml. Also recommended 
are ultra short-acting barbiturates such as pentothal 
or surital administered intravenously at doses of 75 
to 100 mg. 
Tonic and clonic movements during anesthesia 
may be effectively treated with small intravenous 
doses (2 to 5 mg) of diazepam (Valium®). 
Ketamine does not provide adequate control of 
pain originating from the viscera. Therefore, the 
drug is not recommended for use as a sole anesthetic 
in abdominal or thoracic surgery or where visceral 
pain is expected to occur. In order to control visceral 
pain, ketamine may be supplemented with other gen-
eral anesthetic agents. 
In summary, ketamine, a phencyclidine deriva-
tive, is a unique and unusually safe, effective 
anesthetic agent. It is short-acting; it can be given 
either intravenously or intramuscularly; it is rela-
tively easy to control, requiring little in the way 
of adjunctive or supportive drugs or devices. It differs 
markedly from previously established general anes-
thetics because of its selectivity with respect to the 
central nervous system. Ketamine is capable of simul-
taneously depressing cortico-thalamic pathways and 
activating limbic areas, referred to as "dissociation," 
and the resulting state is, therefore, termed "dissocia-
tive" anesthesia. 
Profound analgesia is produced without con-
comitant respiratory depression and without inhibi-
ting reflexes that protect the air passages. The 
cardiovascular system is slightly stimulated. 
Ketamine has proved to be of unique value in 
the anesthetic management of patients, particularly 
infants and children, undergoing a variety of surgical 
and diagnostic procedures involving the head, neck, 
and extremities and those necessitating frequent posi-
tion changes such as are encountered in neurosurgical 
diagnostic procedures and in the treatment of se-
verely burned patients of any age. 
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Properly administered and with due regard for 
its specific advantages as well as its possible disad-
vantages, ketamine may prove superior to conven-
tional anesthetic agents and methods in a variety of 
specific surgical procedures. 
INNOVAR . Innovar is a mixture of two drugs : 
droperidol, a butyrophenone derivative, with strong 
tranquilizing, antiemetic, and adrenergic-blocking 
properties ; and fen/any/, a powerful narcotic analgesic 
related to meperidine which differs from conven-
tional narcotics by its high potency and its fast onset 
and short duration of action. The two drugs are 
mixed in a ratio of 50 to I. When administered in-
travenously in appropriate doses, a state of neuro-
leptanalgesia is produced in which the patient is 
rendered immobile and insensitive to pain. His face 
being expressionless, the patient appears detached 
from his surroundings, yet he remains alert and co-
operative. Respiratory function is depressed and it 
may be necessary to assist or control the respiration 
via a face mask or endotracheal tube. If nitrous 
oxide-oxygen mixtures are added to produce sleep 
and memory deficit, the state of neuroleptanesthesia 
is established. 
Innovar or its separate component drugs, drop-
eridol and fentanyl , can and will provide optimal 
conditions for the patient and surgeon provided 
that certain basic principles and rules are observed 
along with the use of the drugs which may be listed 
as follows: 
1. Adherence to minute details with regard to 
the technique of administering the neuro-
leptanalgesic drugs. 
2. Employing neuroleptanalgesia and anes-
thesia preferably in poor-risk, debilitated, or 
geriatric patients undergoing major, trau-
matic, and prolonged surgery, and avoiding 
their use in pediatric surgery and in short-
lasting, uncomplicated, and minor surgery. 
Technique of Administration of Innovar or Its 
Separate Components, Droperidol and Fentanyl, to 
Produce Neuroleptanalgesia. 
Pre-anesthetic medication: Droperidol alone 
(2.5 to IO mg, depending on age and physical state) 
or Innovar (1 to 2 ml) is given intramuscularly 30 
to 60 minutes prior to surgery. Atropine or scopola-
mine (0.4 to 0.6 mg i.m.) may be added to con-
trol secretions. 
Induction using Innovar: The recommended 
dose of Innovar is 1.0 ml per 25 pounds of body 
weight. This may be reduced to 0.5 ml per 25 pounds 
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of body weight in extremely poor-ri sk and debilitated 
patients. Individuals in good physical state may re-
ceive 1.5 to 2.0 ml per 25 pounds of body weight. 
In a patient of average weight th e total ca lculated 
dose of Innovar ranges from 6 to 8 ml. Debilitated 
and reduced patients may receive 5, 4 , or 3 ml , 
while patients in a satisfacto ry physical state may 
receive 9 or 10 ml. The total dose of lnnovar will 
rarely exceed 10 ml. 
A test dose of I to 2 ml of Innovar injected 
intravenously over a period of 1 minute is always 
used prior to the administration of the full calcul ated 
dose. One to two minutes following the injection of 
the test dose, the blood pressure is recorded , and if 
unchanged, the remainder of the dose is admin-
istered. A blood pressure drop of more than 25 mm 
Hg in response to the intravenous test dose 
usually indicates in adequate circulatory volume re-
quiring rapid intra venous infusion of 500 to 1,000 mm 
of fluids before proceeding with furth er administra-
tion of Innovar. 
The compounded total dose of lnnovar may be 
administered as follows: 
a. Intra venous drip: The solution to be infused 
should contain 10 ml of Innovar added to 
250 ml of 5 % dextrose in water or saline. 
This mi xture is administered by the micro-
drip technique at the rate of 150 to 200 
drops per minute. When increased somnol-
ence and psychic detachment are noticeable 
-usually within 3 to 5 minutes after start 
of the infusion-a local anesthetic ( cocaine 
5 % , lidocaine 4 % ) is topically applied 
either by intralaryngeal spray or by injection 
through the crico-thyroid membrane. When 
the patient's respiratory rate has slowed to 
10 per minute, the intravenous drip is slowed 
to 100 drops per minute. At this point , 
psychic indifference is further enhanced, and 
analges ia has usu ally reached the optim al 
level. The int ravenous drip is then discon-
tinued and the patient is ready for the 
surgical procedure while still responding to 
commands such as "take a deep breath" or 
"open your mouth. " 
b. Intra venous injection: The calculated dose of 
Innovar is injected intravenously in incre-
ments of 1.0 to 2.0 ml over a period of two 
to three minutes. 
Maintenance: In order to hold the level of sur-
gical ana lgesia, fentanyl in doses of 0.05 to 0.1 mg ( 1 
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to 2 ml) is administered intravenously when ch anges 
in vital signs such as increased heart rate, elevated 
blood pressure, increased respiratory rate, or irreg-
ul ar breathing indicate lowering of the pain thresh-
old. It is not recommended th at Jnnovar be admin-
istered fo r maintenance of surgical analges ia because 
of poss ible cumul ative effects of the longer-acting 
droperidol which may result in over-tranquilization 
postoperatively. 
Postoperative period: Usually, analges ia extends 
well into the postoperative period . Therefore, pa-
tients rarely require narcotic analges ics for pain re-
lief. If narcotic analgesics a re administered , their 
dose should be reduced to 114 or 1/ 3 of the usually 
recommended dose. 
Induction using droperidol and fentanyl as 
separate drugs: Induction is started with the intra-
venous administrat ion of droperidol (0 .15 mg per 
kg). The patient 's vital signs are observed for 5 to 6 
minutes and if no change is noted, an initial dose of 
20 to 60 mcg of fentan yl is administered intraven-
ously followed by 20 to 40 mcg doses of fentanyl , 
given at about two-minute intervals at which time 
the patient is considered ready for the operative pro-
cedure. 
Indications. Neuroleptanalgesia should be lim-
ited to patients in whom retention of consciousness 
and cooperation during the surgical procedure is 
desired. Such procedures include: bronchoscopy, 
laryngoscopy. and esophagoscopy; neurodiagnostic 
procedures such as pneumoencephalography and 
carotid arteriography; cardiac catheteri za tion ; stereo-
tactic procedures including cryothalamotomy; resec-
tion of epileptogenic focus; ophthalmic surgery ( in 
conjunction with regiona l anesthesia); middle and 
inner ear surgery ( in conjunction with local anes-
thesia); and oral surgery including tooth extraction 
and other intrao ral surgical procedures involving the 
gingiva and th e tongue. 
Contraindications. Neuroleptanalgesia is con-
traindicated for ambulatory surgery , surgery in in-
fants and chi ldren, acute alcohol delirium or history 
of alcoholism, and narcotic addicts. 
Technique of Administration of lnnovar or Its 
Separate Components, Droperidol and Fentanyl, to 
Produce Neuroleptanesthesia. 
Pre-anesthetic m edicatio n: This is the same as 
th at described under neuroleptanalgesia as is the 
composition of the total dose to be administered for 
producing the neurolept anesthetic state. 
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Ind11ction: Innovar may be administered as fo l-
lows: 
a. Intra venous drip: Prepara tion of th e solut ion 
to be infused and induction are identical with 
the method desc ribed under neuroleptana/gesia. A t 
the time the patient shows signs of somnolence 
and obtundation in response to the infusion, the 
intravenous d rip is slowed to I 00 d rops pe r minute 
and continued at this rate throughout the anes-
thesia course. Ad ministration of nit rous ox ide-oxy-
gen ( 4: 2 ) by face mask is begun , and the pa tient is 
encouraged to take dee p breaths. Within one minute 
the patient usually lapses into unconsciousness with-
out excitement. An int ravenous dose of short-ac ting 
muscle relaxant is administered to fac ilitate endo-
tracheal intubation and to counteract muscle rigidity 
which may develop during this ph ase. As a rule , the 
patient resumes spont aneous brea thing within fi ve to 
eight minutes. D-tubocura rine is admini stered intra-
venously at conventional dosages if muscle relaxa tion 
is needed fo r surgery. When ch anges in vita l signs 
indicate lightening of anes thesia , the dri p rate is in-
creased until vital signs return to norm al. 
b. Intra venous injection: Simil a r to the method 
of neuroleptanalges ia, a tes t dose of I to 2 ml of 
Innova r is administered intravenously ove r a period 
of I minute. Blood pressure is reco rded subsequent to 
this injection and, if found essentially unchanged , 
furth er increments of I to 2 ml of Innovar are ad-
ministered intravenously at 1- to 2-minute intervals. 
By the time the to tal calculated dose has been admin-
istered, the patient shows signs of drows iness and in-
creasing tranquiliza tion. While the patient still is able 
to respond to questioning, the brea thing mask is 
applied and nit rous oxide-oxygen, a t the flow of 4 
liters of nitrous oxide and 2 liters of oxygen per 
minute, is administered. While spontaneous breathing 
is increasingly more depressed, positive pressure 
ventilation via the face mask is begun with the patient 
responding to the comm and to take deep breaths. As 
a rule, after 5 to 8 breath s the patient lapses into un-
consciousness without excitement. Immedi ately prior 
to the loss of consciousness, an intravenous dose of a 
snort-acting muscle relaxant is administe red to fac ili-
tate endotracheal intubation and avoid the develop-
ment of fentanyl-induced muscle rigidity. 
Maintenance: For maintenance of the neuro-
leptanesthetic state, administration of nit rous oxide-
oxygen ( 4 : 2) is continued. F entanyl is administered 
intravenously at doses to l to 2 ml (0.05 to 0 . 1 mg ) 
when changes in vital signs ( increased heart rate, 
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elevated blood pressure, increased respiratory rate, 
or irregul a r brea thing ) indicate lowering of the pain 
threshold . The response to the administration of 
fe ntanyl is usually prompt, and signs of inadequ ate 
pain th reshold elevation disa ppear within 45 to 60 
seco nd s. If the vital sign s continue to indicate insuffi-
c ient analges ia, ano ther increment of I to 2 ml of 
fent anyl is administered intravenously. In an aver-
age patient , administration of supplemental intrave-
nous fentanyl doses is required at 45 to 60 minute 
intervals. F entanyl for maintenance of anes thesia may 
also be given intramuscularly at the same dose as 
mentioned above. Adequate pain threshold eleva-
tion usually is accomplished with this route of ad-
mini stration within 7 to 8 minutes and may last up to 
2 hours. 
In abdominal surgery or oth er procedures re-
quiring muscle relaxation, d-tubocurarine may be ad-
ministe red a t conventional intravenous doses . 
Emergence: Return to consciousness is rapid , as 
soon as the administration of nit rous oxide-oxygen is 
discontinued . Within 3 to 5 minutes the patient is 
usually in contact and ca n answer questions. If respi-
ratory exchange is in adequate, the endotracheal tube 
may be left in pl ace in order to mech anically support 
ventilation until sati sfactory respiratory function is 
rees tablished, at which time the endotracheal tube is 
removed. Levallorph an ( Lorfa n®) may also be given 
at int ravenous doses of I mg to counteract fentanyl-
induced respiratory depress ion. If Lorfan fail s to re-
sto re adequate respiratory function, other factors 
causing respi ratory depress ion should be examined. 
Complete analges ia usually is maintained for 4 
to 6 hours. Nausea and vomiting are rarely en-
countered. 
Indications. Neuroleptanesthesia is indicated for 
the foll owing: bili ary surgery for which halogenated 
a nesthetics may be contraindicated; major, trau-
matic, prolonged surgery involving poor-ri sk patients; 
neurosurgery; cardiovascu lar surgery including open 
heart procedures ; surgery for organ transplantation, 
particul arly kidney transpl ants; middle and inner ear 
surgery ; and emergency surgery involving elderly, 
debilitated, and reduced patients; and patients in 
shock-like states. 
Contraindications. T he cont ra indications for 
neuroleptanesthes ia a re the same as those under 
neuroleptanalgesia. In addition, the use of Innovar 
may be contraindica ted in asthm atic patients since 
it may precipitate an attack. 
Complications. Hypotension is most commonly 
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encountered during induction of neuroleptanes thesia, 
indicat ing inadequate circulatory volume and inabil-
ity of the patient to compensate for peripheral vaso-
dilatation caused by droperidol-induced alpha-adren-
ergic blockade. Treatment should consist of rapid 
infusion of 500 to 1,000 ml of lactated Ringer's solu-
tion or 5 % dextrose in water solution in preference 
of the use of vasopressors. 
Excessive blood pressure elevation, the etiology 
of which is undetermined, has occurred in rare in-
stances. Intermittent admini stration of halothane at 
conventional concentrations or small int ravenous 
doses of chlorpromazine (7.5 to 15 mg i.v.) have 
proved to be effec tive in restoring acceptable blood 
pressm e levels. 
Droperidol may induce extrapyramidal muscle 
acltv//y which may be controlled with anti-
Parkinson agents such as Cogentin®. 
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